Endocannabinoid Tone Regulates Human Sebocyte Biology

Area of Science:

• Dermatology
• Biochemistry
• Molecular Biology

Background:

• Endocannabinoids (eCBs) regulate sebaceous lipid production in human sebaceous glands.
• eCBs are known to significantly increase sebaceous lipid output.
• A putative eCB membrane transporter is hypothesized to control cellular uptake and degradation of eCBs.

Purpose of the Study:

• Investigate the expression of key eCB synthesizing and degrading enzymes in human SZ95 sebocytes.
• Examine the effects of eCB uptake inhibitors on sebocytes.
• Explore the role of the hypothesized eCB membrane transporter.

Main Methods:

• Assessed expression of eCB synthesizing enzymes (NAPE-PLD, DAGL-α, DAGL-β) and degrading enzymes (FAAH, MGL) in SZ95 sebocytes and sebaceous glands.
• Administered eCB uptake inhibitor VDM11 to SZ95 sebocytes.
• Measured sebaceous lipid production, eCB levels, and inflammatory responses to lipopolysaccharide (LPS) with and without VDM11.

Main Results:

• Major eCB synthesizing and degrading enzymes are expressed in SZ95 sebocytes and sebaceous glands.
• VDM11 treatment moderately increased sebaceous lipid production and elevated eCB and related acylethanolamide levels.
• VDM11 inhibited the pro-inflammatory effects of the TLR4 activator lipopolysaccharide (LPS).

Conclusions:

• Inhibition of eCB uptake increases sebaceous lipid production and endogenous eCB levels.
• eCB uptake inhibition demonstrates anti-inflammatory properties.
• eCB uptake inhibitors may offer therapeutic benefits for inflammatory skin conditions associated with dryness.